Roivant Alternatives & Competitors

12 companies similar to Roivant — Reinventing Biopharma

ACELYRIN, INC.

We are a late-stage clinical biopharma company focused on providing life-changing new trea...

103 Acquired $1.10B

Agoura Hills, United Stat...

Biopharma Biotechnology +1

Compare

Emalex Biosciences

Improving people's lives impacted by central nervous system disorders through meaningful s...

54 Series D $300.00M

Chicago, United States

Biopharma Biotechnology +3

Compare

Genmab

Differentiated human antibody therapeutics for the treatment of cancer

2981 IPO $2.28B

Denmark

Biotechnology Pharmaceutical

Lumos Pharma

Transforming Lives with Rare Focus

47 Series B $53.50M

Austin, United States

Biopharma Biotechnology +2

Rival Readout

Competing with Roivant? We do this properly.

10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.

Book a 7-day Readout

Spero Therapeutics

Clinical-stage biotech company focused on rare diseases and diseases with high unmet need

44 IPO $374.60M

Cambridge, United States

Biotechnology Pharmaceutical

Zenas BioPharma

Enabling patients with autoimmune diseases to reimagine life

196 Series C $318.00M

Waltham, United States

Biopharma Health Care +1

Cytokinetics

Empowering Muscle Empowering Lives

779 IPO $3.11B

South San Francisco, Unit...

Biopharma Biotechnology +1

dianosic

"Smartly designed for you"

13 Seed $6.20M

Strasbourg, France

Biotechnology Medical Devices +1

Cullinan Therapeutics

Science That Moves

131 Post-IPO Equity $669.70M

Cambridge, United States

Biopharma Biotechnology +1

Immunocore

Science to Transform Lives

607 IPO $975.60M

Abingdon, United Kingdom

Biotechnology Health Care +1

CV6 Therapeutics, (NI) Ltd.

CV6 Therapeutics is dedicated to improving patients lives through the development of novel...

11 Venture round $8.00M

United Kingdom

Biotechnology Health Care +1

Autolus Therapeutics

Focused on the development of precisely targeted, controlled & highly active T cell therap...

720 Post-IPO Equity $1.07B

London, United Kingdom

Biopharma Biotechnology +1

About Roivant

Roivant, with its slogan "Reinventing Biopharma", is a forward-thinking company dedicated to accelerating health improvements by innovating and delivering medicines and technology swiftly to patients. Established in 2014 and headquartered in the United States, the company bridges gaps in the biopharmaceutical sector th...

Services

Discovery and development of new medicines, Commercialization of pharmaceuticals, Clinical trials management, Establishment of specialized subsidiaries (Vants)

Target Customers

Patients with autoimmune diseases, Patients with pulmonary diseases, Healthcare professionals, Investors interested in biotechnology and pharmaceuticals, Regulatory bodies (e.g. FDA)

Business keywords

Biopharmaceutical Development, Innovative Medicines, Entrepreneurial Biotech, Disease Focused R&D, Uterine Fibroids, Endometriosis, Prostate Cancer, Parkinson’s Disease, Rare Pediatric Conditions, R&D Investment Gap, Technology Deployment, Drug Commercialization, Late-stage Drug Development, Healthcare System Efficiency

Business Model

B2B, B2C, Platform

Revenue Model

Product Sales, Licensing, Performance Based

Frequently Asked Questions

Companies similar to Roivant include ACELYRIN, INC., Emalex Biosciences, Genmab, Lumos Pharma, Spero Therapeutics. They work in Biotechnology and Pharmaceutical and share Roivant's focus on late-stage drug development and innovative medicines.

Bounce Watch lists 12 companies that share Roivant's industries and are closest to it in business tags, services, target customers, business model and size.

From the desk

Mapping a market? Start with a Rival Readout.

In 7 business days we read 10 rivals around Roivant: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.

Book a 7-day Readout Get a free snapshot

Explore Related

Roivant Profile ACELYRIN, INC. Alternatives Emalex Biosciences Alternatives Genmab Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at Roivant on 6 May 2026. The 12 companies listed here were last checked between 7 Jun 2025 and 25 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.